---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-012607"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:53:48.502623+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics: Bexotegrast 320 mg shows significant FVC increase in IPF Phase 2a trial

## Summary
- 320 mg group met primary/safety endpoints; no drug-related severe/serious adverse events over 12 weeks.
- Mean FVC increase of +29.5 mL from baseline vs placebo decline of 110.7 mL (+140 mL vs placebo, p<0.05 at all timepoints).
- No bexotegrast-treated patients had FVCpp decline ≥10%; QLF progression slowed vs placebo (0.20% vs 1.46%).
- PRO-C3 and integrin beta-6 biomarkers reduced at 4 and 12 weeks (p<0.01 and p<0.0001 vs placebo).
- Phase 2b trial planned for mid-2023; final 24-week data from 320 mg cohort expected Q2 2023.

## SEC filing metadata
- accession: 0001193125-23-012607
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312523012607/0001193125-23-012607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312523012607/d418942d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-012607
- JSON: https://secwatch.observer/filing/0001193125-23-012607.json
- Plain text: https://secwatch.observer/filing/0001193125-23-012607.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.